Parkinson's Disease Therapy Using Cell Technology
Transplantation:Mesenchymal Stem Cell Transplantation
About this trial
This is an interventional treatment trial for Transplantation:Mesenchymal Stem Cell Transplantation focused on measuring Parkinson's disease, mesenchymal stem cells, intranasal transplantation, intravenous transplantation, tandem transplantation
Eligibility Criteria
Inclusion Criteria:
- A reliable diagnosis of Parkinson's disease, according to the diagnostic criteria developed by the Brain Bank of the Society for Parkinson's disease of Great Britain (UK Brain Bank Criteria, 1992).
- Stage of the disease according to Hen-Yar: 1.5 - 3.0 stage.
- Rapidly progressive type with a change in the stages of Parkinson's disease in no more than 4 years.
- A good response to levodopa treatment: a positive dopamine test for assessing motor functions by a total score of section 3 of the UPDRS scale in the on- and off-period (not less than 30%).
- The duration of the disease is not more than 8 years with the absence of motor fluctuations and dyskinesias.
- The age of patients is up to 65 years
Exclusion Criteria:
e and parkinsonism-plus. 2. Severe concomitant diseases (congestive heart failure, myocardial infarction, pneumonia, decompensated diabetes mellitus, cachexia, etc.).
3. Autoimmune diseases, a tendency to bleeding, a history of sepsis. 4. Oncological diseases. 5. The presence of acute or exacerbation of the chronic inflammatory process of the sinuses or oral cavity.
6. A positive result for HIV, hepatitis B (HBV), hepatitis C (HCV), syphilis (RW).
7. Cognitive deficit. 8. Mental disorders - hallucinations, behavior disorders. 9. Depression of a pronounced degree (not more than 19 points on the Hamilton scale).
10. Alcoholism, drug addiction, criminal liability in the patient's history. 11. Pregnancy, lactation.
Sites / Locations
- the Belarusian Medical Academy of Postgraduate EducationRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Study group
control group
Autologous MMSC